Day: December 7, 2018

Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-and-durham-stem-students-lead-launch-of-first-genome-editing-experiment-into-space/ CAPE CANAVERAL, FL, USA, December 6th, 2018 – Precision BioSciences today announced that the world’s first genome editing experiment in space has been launched aboard a SpaceX Dragon cargo spacecraft on a Falcon 9 rocket. The mission was launched from Cape

Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

From Startup Neon Therapeutics Link to Full Article: CAMBRIDGE, Mass. and SAN CARLOS, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, and Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that patient dosing has begun in NT-003, Neon’s Phase 1b

Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit

From Startup Dermavant Link to Full Article: https://dermavant.com/dermavant-sciences-to-present-new-data-on-cerdulatinib-for-atopic-dermatitis-and-vitiligo-at-the-3rd-annual-inflammatory-skin-disease-summit/ December 6, 2018 BASEL, Switzerland—Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial

From Startup Axovant Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-announces-feedback-fda-meeting-regarding-axo-lenti-pd Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD Confirmed with FDA that the proposed current manufacturing process and quality control testing is adequate for the clinical program

Eidos Therapeutics Appoints William Lis to Board of Directors

From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-appoints-william-lis-board-directors SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced the appointment of William Lis, to Eidos’ Board of Directors,